Sonic Healthcare Limited earnings date
Sonic Healthcare Limited (SAB) Q4 2026 Earnings Report
DE:SAB Q4 2026 EPS Results
- Actual EPS
- EUR 0.44
- Consensus EPS
- EUR 0.40
- Beat/Miss
- Beat by +EUR 0.04
- One Year Ago EPS
- EUR 0.35
DE:SAB Q4 2026 Revenue Results
- Actual Revenue
- EUR 3.31B
- Expected Revenue
- EUR 3.30B
- Beat/Miss
- Beat by +EUR 5.12M
- YoY Revenue Growth
- +12.65%
Earnings Announcement Details
- Quarter
- Q4 2026
- Date
- 08/19/2026
- Time
- After Close
- Conference Call
- Wednesday, August 19, 2026
Sonic Healthcare Limited's next earnings date is estimated for February 22, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2026 Earnings Call Summary
The call conveyed a largely positive operational and financial picture: strong FY2026 headline results (13% revenue growth, 11% EBITDA growth, 17% NPAT growth), clear progress on acquisitions and synergy capture (notably LADR), solid organic and advanced diagnostics growth, and active capital management. Notable challenges were highlighted—regulatory fee cuts in Switzerland (~CHF 20m), integration and labor cost pressures in the U.K., legacy software impairments (AUD 83m), U.S. market headwinds and uncertainty over potential PAMA cuts, and elevated FY2026 capex and interest costs. Management has provided FY2027 guidance that factors in many of these headwinds and set out remediation initiatives (U.S. operating review, continued synergy capture, digital transformation). On balance, the positives (growth, acquisitions performing, synergy delivery, strong cash/capital actions) outweigh the identified headwinds, although risks remain in specific markets and from regulatory/FX exposures.
Sonic guided FY2027 constant‑currency underlying EBITDA of AUD 1.95–2.03 billion (excluding ~AUD 30 million of back‑office IT transformation costs), with depreciation expected at AUD 810–825 million, amortisation AUD 90–95 million, interest expense up ~6% versus FY2026 and an effective tax rate of ~27%; the guidance excludes potential PAMA fee cuts in the U.S., any property sale gains and assumes no further regulatory changes and current interest rates. Management expects the U.S. operating review to add ~AUD 25–30 million to FY2027 earnings, flagged a Switzerland regulatory revenue impact of CHF 20 million (≈3% of revenue) for FY2027, noted a potential FX EBITDA headwind of ~AUD 40–50 million at current spot rates, expects maintenance CapEx to remain around ~3% of revenue (FY2026 maintenance CapEx ~AUD 351 million) with total PP&E CapEx falling from FY2026’s AUD 631 million as major projects complete, and reiterated capital discipline with a debt cover ratio of 2.2, ~AUD 1.6 billion headroom (pre‑final dividend) and a medium‑term dividend payout target of 70–80% of net profit.
- Strong FY2026 Financial PerformanceTotal revenue up 13% to AUD 10.867 billion; EBITDA up 11% to AUD 1.933 billion (AUD 1.916 billion constant currency); net profit after tax up 17% to AUD 621 million; EPS up 14% to AUD 1.26. FY2026 underlying results in line with guidance.
- Healthy Organic and Advanced Diagnostics GrowthGroup organic revenue grew 5% year-on-year. Advanced diagnostics outperformance: Sonic Genetics (Australia) +15% YoY, Biovis (Germany) +12% YoY, and Mein Direktlabor (Germany direct-to-consumer) >60% YoY.
- Successful M&A and Synergy Delivery (Germany & Switzerland)Completed LADR acquisition in Germany; group Germany revenue grew 43% (organic 5%). Captured >40% of LADR synergies in year one with further synergies to be realized over two years. Switzerland delivered strong margin expansion and organic growth (4% cc, accelerating to 6% in H2) with multiple lab mergers completed.
- U.S. Advanced Diagnostics Momentum and Operating Review ProgressU.S. advanced diagnostics delivered strong organic growth of 16%; >70% of dermatopathology volumes processed via PathologyWatch digital platform. Ongoing U.S. operating review expected to deliver AUD 25–30 million of additional earnings in FY2027.
- Capital Management Actions and Balance Sheet StrengthCompleted sale-and-leaseback of Bowen Hills laboratory for AUD 445 million, crystallizing an AUD 107 million gain and releasing capital; ended year with debt cover ratio of 2.2 and ~AUD 1.6 billion pre-dividend headroom. Final dividend AUD 0.63 (full-year AUD 1.08) franked to 60%.
- Investment in Digital TransformationLaunched major global digital modernization initiative across back office, specialist lab/radiology systems, and AI-enabled clinical front line; planned investment ~AUD 30 million per annum for the next three years to drive efficiency and future growth.
- Strong Operational Performance in Other SegmentsRadiology organic revenue +7% and underlying EBITDA +5%; Sonic Clinical Services revenue +5% with EBITDA up 25% and improved GP consultations per working day (+3.2% H2 vs H1 after incentive program).
DE:SAB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 22, 2027 | 2027 (Q2) | 0.33- | 0.3 | ― | ― |
| Aug 19, 2026 | 2026 (Q4) | 0.400.44 | 0.35 | 25.22% (+0.09) | |
| Feb 18, 2026 | 2026 (Q2) | 0.320.30 | 0.3 | 1.63% (+0.00) | |
| Aug 20, 2025 | 2025 (Q4) | 0.360.35 | 0.36 | -3.69% (-0.01) | |
| Feb 19, 2025 | 2025 (Q2) | 0.310.30 | 0.26 | 15.49% (+0.04) | |
| Aug 21, 2024 | 2024 (Q4) | 0.370.36 | 0.41 | -11.95% (-0.05) | |
| Feb 19, 2024 | 2024 (Q2) | 0.400.26 | 0.49 | -47.34% (-0.23) | |
| Aug 17, 2023 | 2023 (Q4) | 0.450.41 | 0.8 | -48.64% (-0.39) | |
| Feb 15, 2023 | 2023 (Q2) | 0.500.49 | 1.04 | -52.63% (-0.55) | |
| Aug 23, 2022 | 2022 (Q4) | 1.010.80 | 0.82 | -1.42% (-0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

